Compare KBSX & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBSX | RLYB |
|---|---|---|
| Founded | 1976 | 2018 |
| Country | Taiwan | United States |
| Employees | 394 | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 43.9M |
| IPO Year | N/A | 2021 |
| Metric | KBSX | RLYB |
|---|---|---|
| Price | $1.25 | $9.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 93.7K | 54.6K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | $18.65 | N/A |
| Revenue Next Year | $16.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $1.04 | $0.27 |
| 52 Week High | $2.95 | $11.49 |
| Indicator | KBSX | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 63.15 |
| Support Level | $1.08 | $7.93 |
| Resistance Level | $1.42 | $9.25 |
| Average True Range (ATR) | 0.09 | 0.31 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 33.31 | 79.84 |
FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.